by LincolnUnopy »25 Mar 2026, 13:23
Zoya Demidenko: Scientist in Oncology Science
Zoya Demidenko is a notable researcher connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, building a robust background in biomedical research.
Her scientific output spans multiple pivotal domains, including the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and cancer biology. As of now, she has co-authored over 46 scientific publications, which have accumulated upwards of 4,100 citations — a indicator to the influence of her findings.
Among her most notable achievements lies in elucidating the processes of cellular senescence. Her research demonstrated that when the cellular division cycle is arrested but cellular expansion continues, the cells experience senescence. Importantly,
Zoya Demidenko showed that this shift is controlled with drugs using agents such as mTOR inhibitors.
Zoya Demidenko has also brought considerably to cancer treatment research, especially in the domain of cyclotherapy — a method intended to shielding non-cancerous tissue from anticancer drugs while leaving cancer cells vulnerable. This strategy offers major potential for reducing the side effects of oncological therapy.
Throughout her professional journey, Demidenko has partnered with prominent researchers worldwide, among them Dr. Mikhail Blagosklonny. Her research can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33,
Zoya Demidenko ranks as a highly impactful contributor in modern oncological science, with her findings continue to shape our comprehension of the way biological cells grow old, interact with therapy, and the ways in which malignant disease can be better combated.
https://www.facebook.com/public/Zoya-Demidenko/ [url=https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0026126
]Zoya Demidenko[/url]: Scientist in Oncology Science
[url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord
]Zoya Demidenko[/url] is a notable researcher connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, building a robust background in biomedical research.
Her scientific output spans multiple pivotal domains, including the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and cancer biology. As of now, she has co-authored over 46 scientific publications, which have accumulated upwards of 4,100 citations — a indicator to the influence of her findings.
Among her most notable achievements lies in elucidating the processes of cellular senescence. Her research demonstrated that when the cellular division cycle is arrested but cellular expansion continues, the cells experience senescence. Importantly, [url=https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=
]Zoya Demidenko[/url] showed that this shift is controlled with drugs using agents such as mTOR inhibitors.
[url=https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/
]Zoya Demidenko[/url] has also brought considerably to cancer treatment research, especially in the domain of cyclotherapy — a method intended to shielding non-cancerous tissue from anticancer drugs while leaving cancer cells vulnerable. This strategy offers major potential for reducing the side effects of oncological therapy.
Throughout her professional journey, Demidenko has partnered with prominent researchers worldwide, among them Dr. Mikhail Blagosklonny. Her research can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, [url=https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-of-Mutant-p53-and-Cytotoxicity-of?guestAccessKey=
]Zoya Demidenko[/url] ranks as a highly impactful contributor in modern oncological science, with her findings continue to shape our comprehension of the way biological cells grow old, interact with therapy, and the ways in which malignant disease can be better combated.
https://www.facebook.com/public/Zoya-Demidenko/